Mochida Pharmaceutical has formed a partnership with US-based PBC Biomed for US sales of ReFeel, a nerve regeneration-promoting material. Mochida's US subsidiary plans to work with PBC Biomed to begin full-scale sales, and further developments will be closely watched.
Mochida Pharmaceutical announced on the 9th that it had signed a sales partnership agreement with US-based PBC Biomed for ReFeel, a nerve regeneration-promoting material. As a result, Mochida's US subsidiary will work with PBC Biomed to establish a framework for commencing full-scale sales in the US market.
The specific terms of the partnership agreement were not disclosed in the report. The two companies explained that they plan to advance the market launch of ReFeel through their collaborative framework. ReFeel is positioned as a therapeutic material in the field of nerve regeneration, and the companies' cooperation could contribute to its wider adoption in the US market.